Michelle Tavcar
Louisville, KYNPI 1013595768
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations.
Across 194 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$713
- Novartis$458
- Pfizer$332
- Gilead$290
- Regeneron Healthcare Solutions, Inc.$250
- AbbVie$240
- plus $3K from 36 others
What the payments were for
- Food & beverage$5,08595%
- Education$2705%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 29 | $713 |
| Novartis | 17 | $458 |
| Pfizer | 14 | $332 |
| Gilead | 4 | $290 |
| Regeneron Healthcare Solutions, Inc. | 7 | $250 |
| AbbVie | 9 | $240 |
| Bristol Myers Squibb | 8 | $238 |
| Sanofi | 3 | $233 |
| Incyte Corporation | 9 | $220 |
| Boehringer Ingelheim | 6 | $187 |
| Johnson & Johnson | 7 | $184 |
| Merck | 8 | $170 |
| Recordati_rare_diseases_inc. | 3 | $163 |
| AstraZeneca(2 entities) | 4 | $153 |
| EMD Serono, Inc. | 4 | $116 |
| Pharmaessentia USA Corporation | 5 | $113 |
| Bayer | 5 | $106 |
| Novocure Inc. | 1 | $97 |
| Coherus Oncology, Inc. | 4 | $87 |
| Genentech USA, Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Puma Biotechnology, Inc. | 4 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Syndax Pharmaceuticals, Inc. | 1 | $63 |
| Legend Biotech USA Inc. | 3 | $62 |
| Eisai Inc. | 4 | $60 |
| Blueprint Medicines Corporation | 3 | $60 |
| Sobi, Inc | 2 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $51 |
| AVEO Pharmaceuticals, Inc. | 3 | $49 |
| Lilly USA, LLC | 2 | $44 |
| Agios Pharmaceuticals, Inc. | 2 | $36 |
| Immunocore Limited | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Genmab U.S., Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Sandoz | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Trodelvy$145
- KISQALI$140
- LIBTAYO$126
- PANHEMATIN$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.